Trial design and participants
SECONDARY
This is a predefined secondary analysis of a single-center, randomized, double-blind, placebo-controlled, parallel-group trial conducted at the University Hospital Basel, Switzerland, from June 2017 to June 2022, investigating the effect of a 12-week treatment with dulaglutide on smoking abstinence when added to standard smoking cessation therapy (i.e., varenicline plus behavioral counselling). A detailed description of the study methodology has been published elsewhere (